This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the first quarter. Results will provide clarity on the impact of coronavirus on the company's business.
Will Pfizer's (PFE) BioPharma Unit Q1 Earnings Increase?
by Zacks Equity Research
In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the first quarter, while in non-oncology, Xeljanz and Eliquis alliance revenues are likely to have supported the top line.
Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN
by Kinjel Shah
Eli Lilly (LLY) announces Q1 results. Pfizer (PFE) and Novartis (NVS) provide update on their studies/plans to make coronavirus treatments or vaccines.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $36.71, moving +1.27% from the previous trading session.
Pfizer/BioNTech to Begin Coronavirus Vaccine Study in Germany
by Zacks Equity Research
Pfizer (PFE) and BioNTech receive approval from regulatory authority in Germany to start an early-stage clinical study to evaluate their mRNA-based vaccine candidates for COVID-19.
What's in the Cards for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Pfizer's (PFE) performance when it reports first-quarter results.
Healthcare ETFs Looks Strong Ahead of Q1 Earnings
by Sweta Killa
The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.
Myovant Eyes Relugolix Approval for Advanced Prostate Cancer
by Zacks Equity Research
Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix as a treatment for advanced prostate cancer.
Coronavirus Makes Biotech ETFs Red Hot
by Sweta Killa
The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.
Novartis To Initiate Hydroxychloroquine Study for Coronavirus
by Zacks Equity Research
Novartis (NVS) announces FDA's approval to evaluate hydroxychloroquine in hospitalized patients with COVID-19 in a late-stage study. The company is evaluating several of its drugs to treat COVID-19.
5 Best Leveraged ETF Areas of Last Week
by Sanghamitra Saha
If investors can identify the trending investing area amid all the coronavirus chaos, they can easily take a leveraged position on that and beat the broader market.
Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts
by Kinjel Shah
J&J (JNJ) announces Q1 results. Several companies offer update on their studies/plans to make coronavirus treatments or vaccines
Optimism Back in Wall Street? ETFs Areas to Win the Most
by Sanghamitra Saha
Wall Street is likely to stage a relief rally on hopes of reopening of American businesses, improving virus outlook and chances of treatment coming on stream.
Pfizer (PFE) Stock Moves -1.26%: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $35.98, marking a -1.26% move from the previous day.
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up
by Ritujay Ghosh
If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.
The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy
Will Stem Cell Therapies Aid in Fight Against Coronavirus?
by Ekta Bagri
With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.
Pfizer (PFE) Progressing Well With its Coronavirus Program
by Zacks Equity Research
Pfizer (PFE) is developing a vaccine as well as other treatment options targeting coronavirus infection, COVID-19. However, all developments are in pre-clinical stages.
Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak
by Zacks Equity Research
Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
Top Analyst Reports for Alibaba, Pfizer & S&P Global
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), Pfizer (PFE) and S&P Global (SPGI).
Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer
by Zacks Equity Research
Pfizer (PFE) secures an FDA approval for Braftovi combined with Lilly's Erbitux to treat BRAFV600E-mutant metastatic colorectal cancer in patients who received prior therapy.
J&J (JNJ) Q1 Earnings May Indicate Coronavirus Impact on Pharma
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on J&J's (JNJ) performance when it reports first-quarter results.
Merck's Keytruda Gets FDA's Priority Review for Solid Tumors
by Zacks Equity Research
Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's priority review.
Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.